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Management of patients with adult respiratory distress
syndrome (ARDS) has been a therapeutic challenge for
years. Despite scientific interest, there has been a lack of
high quality clinical studies demonstrating a mortality benefit.
In 2000 a large trial funded by the US National Institutes of
Health (NIH) [1] demonstrated a 9% reduction in absolute
mortality in patients ventilated with a low tidal volume
strategy (6 ml/kg versus 12 ml/kg). This clinical finding is
supported by many animal experiments that have also shown
that mechanical ventilation, in particular with smaller tidal
volumes, can prevent or minimize lung injury.
Although the mechanisms of ventilator-induced lung injury
remain incompletely understood, over-distention and
repeated opening and collapse of alveoli can damage the
alveolar–capillary barrier and initiate or amplify a local and
systemic inflammation. Data presented by Frank and Matthay
in their review [2] (this issue) also provide strong evidence
from experimental models that limiting alveolar stretch is
associated with a significant decline in inflammatory cytokine
release. This decline in release of cytokines has also recently
been shown to occur not only in animal models but also in
humans. In a study conducted by Ranieri and coworkers [3],
44 patients with ARDS treated with lung protective
strategies were found to exhibit a decline in inflammatory
cytokines in lung lavage fluid. Damage to the
alveolar–capillary barrier in combination with release of
inflammatory cytokines is theorized to be a major contributor
to the development of the multiorgan dysfunction that leads
to death in patients with ARDS [4].
Lung protective strategies are considered by many to be
standard of care, although clinicians may have modified the
ARDS Network protocol [1]. The ARDS Network protocol
was complex, and differences in management between the
experimental and control groups were not limited to changes
in the volume of tidal breaths or in plateau pressures.
Therefore, many interventions other than the lower tidal
volume may well have contributed to the mortality benefit. For
example, it may be very tempting for clinicians to adopt a
ventilator strategy that minimizes tidal volume, as was
employed in the ARDS Network protocol, but to permit much
higher arterial carbon dioxide tensions than were allowed in
that protocol. After all, there is good experimental evidence
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Abstract
In the present issue of Critical Care, Frank and Matthay review the physiologic mechanisms that lead
to ventilator-induced lung injury. Our greater understanding of basic physiologic principles has already
had a major impact on the treatment of critically ill patients. Novel strategies to limit ventilator-induced
lung injury have now been shown to improve survival. However, there has been debate in the literature
regarding the safety and efficacy of the Acute Respiratory Distress Syndrome (ARDS) Network study
protocol in reducing ventilator-induced lung injury. The issues surrounding the ARDS Network protocol
and a recent meta-analysis criticizing its use are presented. As clinicians, we now have the
responsibility to ensure that our patients benefit from these recent developments.
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that permissive hypercapnia not only may protect the lung but
also may even have its own therapeutic benefit [5]. However,
failure to increase the respiratory rate as dictated by the
ARDS Network protocol may negate other potentially
beneficial effects of the protocol. Indeed, a follow-up study of
some patients ventilated according to the ARDS Network
protocol [6] provided evidence that the more rapid respiratory
rate led to the development of intrinsic positive end-expiratory
pressure (PEEP). Did the higher total PEEP in the
experimental group contribute to the reduction in mortality?
In recent weeks the ARDS Network protocol has come under
much scrutiny. A meta-analysis sponsored by the NIH
suggests that adopting a ventilation strategy with low tidal
volumes may not reduce mortality [7]. In that study, the five
trials testing mechanical ventilation with low tidal volumes
[1,8–11] were classified into two groups: two ‘beneficial’
trials, which showed an improvement in survival; and three
‘nonbeneficial’ trials, which showed no survival benefits. The
authors of the report observed that plateau pressures in the
control groups of the two beneficial trials were larger than
those used in the control groups of the nonbeneficial trials.
Furthermore, no difference was observed in the plateau
pressures between the beneficial and nonbeneficial trials.
They concluded that the greater survival of the experimental
groups in the two beneficial studies was not related to an
experimental ventilation strategy with low tidal volumes.
Rather, it was ascribed to the deleterious consequences of
adopting a control strategy with higher tidal volumes resulting
in excessive plateau pressures. In our opinion, such
conclusions may be premature and unfounded. Indeed, the
plateau pressure was not the only variable that differed
between the control groups of the beneficial and
nonbeneficial trials. The ARDS Network as well as the other
study protocols documented in the literature involved a
complex interplay of many physiologic parameters. To
attempt to reduce them to a single factor – the plateau
pressure – may be overly simplistic. Before attributing the
survival benefits solely to differences in plateau pressure, one
would also have to account for all other clinical and protocol
variables that may have differed between the control groups
of the beneficial and nonbeneficial trials. It is also difficult to
understand why we should ascribe the mortality benefit seen
in the ARDS Network experimental group to the suboptimal
treatment of the control arm, given that this control arm
experienced one of the lowest mortality rates documented in
the literature to date. Should clinicians adopt a strategy that
only limits tidal volume or should they adopt the NIH protocol
in its entirety?
Considering the methodological shortcomings of NIH meta-
analysis and the absence of other large clinical trials showing
a reduction in mortality, we believe that the optimal decision
remains to use the ARDS Network protocol in its entirety.
Even slight alterations in the protocol may have
consequences that simply cannot be appreciated, given the
complexity of the treatment and of the body’s response.
There remain many outstanding clinical questions in ARDS.
The transition of physiologic concepts derived from basic
science research into management strategies has already
significantly impacted on the care of patients with ARDS.
Standard of care will continue to evolve as the answers to
outstanding questions concerning the exact role of alternate
therapies (e.g. high frequency oscillation ventilation,
recombinant surfactant, open-lung strategies, prone
positioning, steroids, and ideal PEEP) become better
defined. Because of the large number of possible therapeutic
options and the innate difficulty in performing high quality
clinical trials in the critically ill, it becomes impossible to test
all possible therapeutic options in the clinical arena.
Therefore, it is only through a greater understanding of basic
scientific concepts that researchers will become able to
identify the few questions that are most likely to be of clinical
benefit and that should be systematically tested in large, high
quality epidemiological studies with sufficient power to
demonstrate clinically significant differences. Until more data
become available, we believe that clinicians should adhere to
the ARDS Network protocol in its entirety, because this is the
only evidence available that shows that lives can be saved.
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